| Literature DB >> 36077119 |
Ileana Ielo1, Giovanna Calabrese1, Giovanna De Luca1, Sabrina Conoci1,2,3.
Abstract
Bone tissue is a nanocomposite consisting of an organic and inorganic matrix, in which the collagen component and the mineral phase are organized into complex and porous structures. Hydroxyapatite (HA) is the most used ceramic biomaterial since it mimics the mineral composition of the bone in vertebrates. However, this biomimetic material has poor mechanical properties, such as low tensile and compressive strength, which make it not suitable for bone tissue engineering (BTE). For this reason, HA is often used in combination with different polymers and crosslinkers in the form of composites to improve their mechanical properties and the overall performance of the implantable biomaterials developed for orthopedic applications. This review summarizes recent advances in HA-based biocomposites for bone regeneration, addressing the most widely employed inorganic matrices, the natural and synthetic polymers used as reinforcing components, and the crosslinkers added to improve the mechanical properties of the scaffolds. Besides presenting the main physical and chemical methods in tissue engineering applications, this survey shows that HA biocomposites are generally biocompatible, as per most in vitro and in vivo studies involving animal models and that the results of clinical studies on humans sometimes remain controversial. We believe this review will be helpful as introductory information for scientists studying HA materials in the biomedical field.Entities:
Keywords: bioceramics; biocomposites scaffold; bone tissue regeneration; hydroxyapatite; osteoinduction; osteoregeneration
Mesh:
Substances:
Year: 2022 PMID: 36077119 PMCID: PMC9456225 DOI: 10.3390/ijms23179721
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Comparison between synthetic CaP and bone mechanical properties.
| Material | Compressive Strength (MPa) | Tensile Strength (MPa) | References |
|---|---|---|---|
| Cancellous bone | 41.4 | 3.5 | [ |
| Porous HA | 6.9–68.9 | 2.48 | [ |
| Porous TCP | 2.9 | N/A | [ |
Abbreviations: HA, hydroxyapatite; TCP, tricalcium phosphates.
Details of different natural polymers recently used in the preparation of hydroxyapatite biocomposite scaffolds.
| Polymer and | Crosslinker | Fabrication Method | In Vitro Study | In Vivo Study | Refs |
|---|---|---|---|---|---|
| Col, CS, | Dehydrothermally (DHT) crosslinked under vacuum for 48 h at 120 °C. | Lyophilization | - | - | [ |
| Col | BDDGE 2.5 mM at 4 °C for 19 h. | Lyophilization | hMSCs Human Mesenchymal Stem Cells | Rabbit (lumbar spine) | [ |
| Col, chitin | Epichlorohydrin/chitin (10:1 molar ratio) at 60 °C for 6 h. | Lyophilization | MC 3T3 osteoblast precursor cell line | Male SD Rats (tibial defect) | [ |
| Fish Col, | N-hydroxysuccinimide (NHS) 10 mM, EDC 10 mM at 4 °C for 24 h. | Electrospinning | BMSCs, HGF | - | [ |
| Col, | Ribose 0.2 M, acetone 10 wt.%, and ammonia 2 wt.% at rt for 24 h. | Biomimetic mineralization | Osteoblasts | - | [ |
| Col, | Genipin 1 wt.% | 3D-printing | BMSC | Rat (critical size calvarial defect) | [ |
| Col, CS, Hyaluronic acid (HyA) | - | Lyophilization | - | - | [ |
| CS, Polyvinyl alcohol (PVA), 3-aminopropyltriethoxysilane | Citric acid 1.5 wt./v.% at rt for 2 h. | Electrospinning | Fibroblast cells derived from human lung tissue | - | [ |
| CS, Alg, Dopamine | CaCl2 solution (5 wt.%) for 5 h at rt. | Lyophilization | L929 cells Subclone of parental strain L | Rabbits (femur) | [ |
| CS, PVA, PLA | - | Lyophilization | MC3T3-E1 subclone mouse pre-osteoblasts | - | [ |
| CS, Sr2+, Mg2+, Zn2+ | Genipin 1 wt.% at 37 °C for 12 h. | In situ precipitation | MC 3T3-E1 | - | [ |
| Furan-modified Alg, Mg2+, Poly(propylene oxide)-b-poly(ethylene oxide)-b-poly(propylene oxide) bifunctional maleimide | EDC 8 mM at rt for 1 h. | Lyophilization | MC 3T3-E1 | - | [ |
| Alg | CaCl2 0.1 M solution at 40 °C overnight. | Lyophilization | - | Rats (cortical bone) | [ |
| Alg, PVA | CaCl2 100 mM solution at rt for 1 h. | 3D-printing | MC 3T3 | - | [ |
| Fibrin, Alg | 0.2% | Lyophilization | MC 3T3 | - | [ |
| Alg, CS | CaCl2 1 wt.% solution at rt for 15 min. | Lyophilization | MG63 human osteosarcoma cell line | - | [ |
| Alg, CS | CaCl2 15 wt.% solution at rt for 30 min. | Lyophilization | BMSCs | - | [ |
| Alg, | D-Gluconic acid δ-lactone, CaCl2 10 mM solution at rt for 1 h. | Lyophilization | BMSCs | - | [ |
| Col, CS, HyA | EDC 50 mM, NHS 25 mM in ethanol 98 % at rt for 4 h. | Lyophilization | SaOS-2 | - | [ |
| Poly(L-lactic acid)-co-poly(ε-caprolactone), silk fibroin, HyA | - | Electrospinning | hFOBs | - | [ |
| HyA | - | Lyophilization | hUCMSCs | - | [ |
| HyA, CS, Chondroitin sulfate | EDC, NHS (2:1 molar ratio) at rt for 5 h. | Lyophilization | Osteoblasts | - | [ |
Abbreviations: Col, collagen; CS, chitosan; MWCNT, multiwalled carbon nanotubes; DHT, dehydrothermally; BDDGE, 1,4-butanediol diglycidyl ether; hMSCs, human mesenchymal stem cells; SD, sprague dawley; PLGA, Poly(lactide-co-glycolide); NHS, N-hydroxysuccinimide; EDC, 1-ethyl-3-(3-dimethylamino propyl) carbodiimide hydrochloride; BMSCs, Bone mesenchymal stem cells; HGF, human gingiva fibroblasts cells; GO, graphene oxide; BMSC, bone marrow stromal cells; HyA, Hyaluronic acid; PVA, polyvinyl alcohol; Alg, alginate; PLA, poly lactic acid); SaOS-2, human osteosarcoma cell line; hFOBs, human fetal osteoblasts; hUCMSCs, human umbilical cord mesenchymal stromal cells.
Figure 1Chemical structure of (a) Col [57]; (b) CS; (c) Alg; (d) HyA.
Details of different synthetic polymers recently used in the preparation of hydroxyapatite biocomposite scaffolds.
| Polymer and Additives | Fabrication Method | In Vitro Study | In Vivo Study | Refs |
|---|---|---|---|---|
| PCL | Precision extrusion deposition | Osteoblasts | - | [ |
| PCL, ZnO nanoparticles | Electrospinning | Bone-derived MG-63 (human osteosarcoma) cells | - | [ |
| PCL, Alg | Electrospinning | hDPSCs Human dental pulp stem cells | - | [ |
| PCL, Co2+ | Electrochemical deposition | MG-63 cells | - | [ |
| PCL, poly(glycerol sebacate), Simvastatin | Electrospinning | MC 3T3-E1 cells | - | [ |
| PCL | 3D-printing | Osteoblast cells | Rats (calvarial defect) | [ |
| PCL, MgO | 3D-printing | MC 3T3-E1 cells | - | [ |
| PLA, | Drying under vacuum | MC 3T3-E1 cells | - | [ |
| PLA, Alg | 3D-printing | - | [ | |
| PLA, polypyrrole | Electrospinning | Fibroblast-like cells | - | [ |
| PLA, nanoclay | Lyophilization | MG-63 cells | Albino male rats (critical size calvarial defect) | [ |
| PLA | 3D-printing | BMSCs | - | [ |
| PLA | 3D-printing | BMSCs | White rabbits (tibial periosteum defect) | [ |
| PLA, Silk | 3D-printing | - | - | [ |
| Poly-hydroxybutyrate (PHB) | Electrospinning | BMMSCs | - | [ |
| PHB | Thermally-induced phase separation | MC 3T3-E1 cells | - | [ |
| PHB, Alg, mesenchymal stem cells | Hydrogel synthesis | MSCs | Rats (critical size calvarial defect) | [ |
| PHB | Solution casting | L929 fibroblasts cells | - | [ |
| PHB | Electrospinning | Osteoblasts | - | [ |
| PHB | Compression molding | MMSCs | Mice (tibial bone defect) | [ |
| PLGA | Electrospinning | MC 3T3-E1 cells | - | [ |
| PLGA, 3,4-hydroxyphenalyalanine | High-voltage electrostatic technique | MC 3T3-E1 cells | Rat (calvarial defects) | [ |
| PLGA, Polydopamine, Doxorubicin | Electrospinning | MG-63 cells | Mouse (skull defects) | [ |
| PLGA | Electrospinning | L929 fibroblasts cells | - | [ |
| PLGA | Electrospinning | hPCs Haemopoietic Progenitor Cells | patients (>18 years) requiring monolateral or bilateral maxillary sinus floor augmentation without comorbid disease | [ |
Abbreviations: PCL, poly-ε-caprolactone; Alg, alginate; hDPSCs, human dental pulp stem cells; PLA, poly lactic acid; BMSCs, bone mesenchymal stem cells; PHB, poly-hydroxybutyrate; BMMSCs, bone marrow mesenchymal stem cells; MSCs, mesenchymal stem cells; MMSCs, multipotent mesenchymal stromal cells; PLGA, Poly(lactide-co-glycolide); hPCs, haemopoietic progenitor cells.
Figure 2Chemical structure of (a) PLC; (b) PLA; (c) PHB; (d) PLGA.
Figure 3Schematic representation of the crosslinking reaction through dehydrothermal treatment.
Figure 4Schematic representation of the GTA-crosslinking reaction.
Figure 5EDC chemical structure (a) and schematic representation of the EDC-crosslinking reaction (b) with or without NHS.
Figure 6Schematic representation of BDDGE-crosslinking reaction.
Figure 7Schematic representation of the Genipin crosslinking reaction.